Shares of Precigen Inc. (PGEN) have been on a tear since last August, fueled by a regulatory breakthrough for its lead drug, PAPZIMEOS.
On Aug.15, 2025, PAPZIMEOS received full approval from the FDA for the treatment of adults with recurrent respiratory papillomatosis (RRP). Although its Biologics License Application was under review via the accelerated approval pathway, the agency granted full approval - thereby eliminating the need for a confirmatory clinical trial.
For comments and feedback contact: editorial@rttnews.com
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.